Navigation Links
Roche clinical trial registry and results database launched

Within only three months after deciding to create an electronic database, Roche is launching a public clinical trial registry and results database using an independent host, CenterWatch. On www.roche-trials.com information on Roche’s clinical trials can be accessed by anyone, anywhere, with no password restrictions. This site is designed to give patients and healthcare providers ready access to information they need, in terms they can understand.

Ed Holdener, Head of Global Pharma Development at Roche, said: “We are proud to go live with our publicly accessible protocol registry and clinical trial results database today. Transparency has always been and continues to be a priority for us. In January, we announced our plans to have an independent host for the database and since then, we selected CenterWatch, a company with a wealth of experience in the area of data management and the publication of clinical trial information. So for the first time ever, there is now a global and publicly accessible database, containing comprehensive information about Roche’s clinical trials?

Roche expects that the huge task of publishing data from more than 30 medicines, on a product by product level from a large number of global and local trials, will take approximately a year. Roche will also continue to contribute information to established databases (i.e. www.clinicaltrials.gov)

Information that can be found in the electronic database
Starting with Fuzeon and Bondronat, clinical trial information will be added in a staged approach on the databases and will ultimately include protocol information and results from all Phase II to Phase IV clinical trials completed after 1 October, 2004. In addition, data from all Phase II to Phase IV clinical trials for medicines first marketed after 1 October, 2002 will be included retrospectively. The clinical trial registry and results database will also include interventional clinical studies from Roche Diagnostics.< /p>

Roche approach and possible industry solution
Roche is taking a leadership role in the industry’s efforts to ensure transparency with its global approach, which is consistent with the information disclosure principles published earlier this year by the European Federation of Pharmaceutical Industry Associations (EFPIA).
The Roche strategy may model an industry-wide solution. Roche would support and participate in a future industry solution that provides a public database in which all companies can publish both national and international protocol information and trial results. Roche would be delighted if this independent solution would lead other pharmaceutical companies to use the CenterWatch repository to register ongoing clinical trials and report results of trials.
CenterWatch is a leader in web design and experienced in the implementation of websites for clinical trial listings and clinical trial results, and already has an established reputation as an independent source that the public trusts for clinical trial listings and results. Having CenterWatch host Roche’s clinical trials databases provides the widest possible exposure, and makes it easy for the public to obtain important information in this area.

Strict adherence to regulations of clinical trials
Roche works to ensure that all its activities are performed in accordance with ethical and regulatory requirements. Moreover, Roche is strongly committed to verifying adherence to compliance policies. Adequate and ongoing peer review is a key prerequisite for maintaining high ethical standards in Roche’s clinical trials and development activities.
In addition, Roche adheres to the “Declaration of Helsinki? a statement developed by the World Medical Association on ethical principles to provide guidance to physicians and other participants in medical research involving human subjects. Roche also strictly follows the rules of good clinical practice (GCP), which ensure the protection of patients?safety and rights.


'"/>

Source:Roche


Related biology news :

1. Rochester scientists develop fast-working biosensor
2. NIAID begins clinical trial of West Nile virus vaccine
3. Compound might defeat African sleeping sickness, clinical trial beginning this month
4. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
5. Dalai Lama, top scientists to discuss science & clinical applications of meditation
6. Stem cells electric abilities might help their safe clinical use
7. New malaria vaccine shows promise in early clinical trial
8. Preclinical study of a new brain tumor therapy
9. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
10. Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial
11. NIH announces phase III clinical trial of creatine for Parkinsons disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology: